Research
Cellular
SGLT2 inhibitors reduce cardiovascular morbidity and mortality in patients with type 2 diabetes.
SGLT2 inhibitors can be considered in treatment plans to improve cardiovascular outcomes in diabetic patients.
StrongSupportsmedium confidence
A number of cardiovascular outcome trials in patients with type 2 diabetes have been studied with SGLT2 inhibitors reducing cardiovascular morbidity and mortality.
Why this rating
Based on the mention of cardiovascular outcome trials.
Source
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Ban Liu et al. · Current Topics in Medicinal Chemistry · 2019
DOI 10.2174/1568026619666190828161409
reviewCited 41×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →